Polymorphisms in drug transporter genes (ABCB1, SLCO1B1 and ABCC2) and hepatitis induced by antituberculosis drugs - 02/02/12
Corresponding author. Tel.: +82 41 550 3923; fax: +82 41 556 3256.Summary |
Unusual drug accumulation is a common mechanism underlying serious drug-induced liver injury. Polymorphisms in three drug transporter genes (ABCB1, SLCO1B1 and ABCC2) may be risk markers for hepatitis induced by the unusual accumulation of anti-tuberculosis drugs (ATDs). We therefore investigated whether polymorphisms and haplotypes of these genes are associated with ATD-induced hepatitis by comparing the frequencies and distributions of single nucleotide polymorphisms and haplotypes of these three drug transporter genes among 67 patients with ATD-induced hepatitis and 159 patients tolerant to ATDs using a multivariate logistic regression analysis. We found that the frequencies of polymorphisms and haplotypes of ABCB1, SLCO1B1 and ABCC2 were similar in patients with ATD-induced hepatitis and ATD-tolerant controls. The present results suggest that these drug transporters do not play important roles in the pathogenesis of ATD-induced hepatitis in Korean patients.
Le texte complet de cet article est disponible en PDF.Keywords : Drug transporter, Antituberculosis drug, Hepatitis
Plan
Vol 92 - N° 1
P. 100-104 - janvier 2012 Retour au numéro
Article précédent
- Is RORγ a therapeutic target for treating Mycobacterium tuberculosis infections?
- Paul W. Baures
- Assessment of vaccine testing at three laboratories using the guinea pig model of tuberculosis
- Ajay Grover, JoLynn Troudt, Kimberly Arnett, Linda Izzo, Megan Lucas, Katie Strain, Christine McFarland, Yper Hall, David McMurray, Ann Williams, Karen Dobos, Angelo Izzo
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?